Myelofibrosis is a severe and very rare haematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking. The H12O-CNIO ...
Dec 19, 2018
0
5
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.
Dec 14, 2018
2
11
Researchers investigating new treatments for neuroblastoma—one of the most common childhood cancers—have found that a combination of two drugs made tumours disappear in mice, making it more effective than any other drugs ...
Nov 15, 2018
0
2
Scientists have discovered a drug combination that could halt the progression of fibrosis—a condition believed to be responsible for almost half of all deaths—according to a study published in the journal European Urology.
Nov 5, 2018
0
1
By the age of 65, at least half of us will suffer from two or more long-term diseases. And the chance of having multi-morbidity, as it is known, increases with age.
Oct 18, 2018
0
0
Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers in the body, threatening to rise to dangerous levels ...
Sep 26, 2018
0
95
A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to treat a patient with advanced cancer, completely halting disease ...
Sep 4, 2018
0
6
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, ...
Aug 13, 2018
0
2
Bacteria—especially Gram-negative strains—are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed. Faced with these challenges, investigators are studying ...
Aug 10, 2018
0
3
New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration ...
Jul 25, 2018
0
4
